References
- Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter 2013;164:e413-28
- Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64
- Ramos-Casals M, Brito-Zerón P, Muñoz S, et al; BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008;87:345-64
- Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52
- Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, et al; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188-93
- Wendling D, Paccou J, Berthelot JM, et al; CRI. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
- Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 2014: published online 8 October 2014, 10.1185/03007995.2014.969368
- Berg IJ, Semb AG, van der Heijde D, et al. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study. Semin Arthritis Rheum 2014: published online 20 May 2014, 10.1016/j.semarthrit.2014.05.017
- Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87
- Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51
- Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
- Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47:731-2
- Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
- Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121:785-96.e3